Insilico’s AI-designed drug shows an early aging signal in lung disease patients
Insilico Medicine's AI-designed drug, rentosertib, showed an early signal of shifting biological aging markers towards younger estimates in a small study of idiopathic pulmonary fibrosis patients. While promising for AI in drug discovery, researchers caution that the findings do not prove the drug slows aging and further investigation is needed.
Why it matters
This represents a significant step in AI-driven drug discovery, demonstrating a concrete link between AI design and patient testing. If validated, it could revolutionize how new treatments are developed, particularly for complex diseases like IPF and potentially aging itself.
Insilico’s rentosertib shifted aging clock estimates in a small study, offering an early glimpse of AI’s medical promise while leaving major questions.
Insilico Medicine has published an exploratory analysis showing that rentosertib, a drug candidate designed with AI, shifted blood markers toward younger age estimates in patients with idiopathic pulmonary fibrosis. The September 7 study in Nature Biotechnology offers an intriguing signal, but it cannot establish that the drug slows aging.
Rentosertib is being developed for idiopathic pulmonary fibrosis, or IPF, a disease in which scarring progressively damages the lungs. Investigators report that AI helped identify the target protein, TNIK, and design a molecule to inhibit it. That gives the research a concrete connection between AI drug discovery and testing in patients.
Originally covered in The Rundown’s September 8, 2026 newsletter .
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in